Skip to content
DataLookout
Menu

ONCOSTIMNCT07912775

Transcranial Direct Current Stimulation for Chemotherapy-Related Chronic Pain in Cancer Survivors

StatusNot Yet Recruiting
PhaseNot applicable
Primary completion (estimated)
Track this trial

Free. We email you which fields changed when ClinicalTrials.gov updates this record.

Record History

All 1 version: 1 with changes below.

  1. Study First Submitted

Endpoints

Primary

Change in pain intensity (Visual Analogue Scale, VAS) after the acute phase
Timeframe: Baseline (T0) and after the acute phase at 1 week (T1)

Secondary (10)

Change in pain intensity (Visual Analogue Scale, VAS) from the end of the acute phase through maintenance
Change in pain severity and interference (Brief Pain Inventory, BPI)
Change in anxiety and depression (Hospital Anxiety and Depression Scale, HADS)
Change in global cognitive function (Montreal Cognitive Assessment, Spanish version, MoCA-S)
Change in information processing speed (Symbol Digit Modalities Test, SDMT)
Show 5 moreShow less
Change in sustained attention and working memory (Paced Auditory Serial Addition Test, PASAT-3)
Change in verbal fluency (Controlled Oral Word Association Test, COWAT)
Change in verbal learning and memory (Rey Auditory Verbal Learning Test, RAVLT)
Change in quality of life (World Health Organization Quality of Life - Brief Version, WHOQOL-BREF)
Change in diurnal salivary cortisol

Arms and interventions

Active tDCSExperimental

Phase I (acute, double-blind): 5 consecutive daily sessions of active tDCS (2 mA, 20 minutes, 30-second ramp-up and ramp-down) combined with the Sternberg working-memory task (10 minutes at rest, then 10 minutes performing the task). Responders (at least 2-point reduction on the pain VAS from baseline) continue to Phase III (maintenance, open-label): active tDCS with the same scheme twice a week for up to 2 months.

Sham tDCSSham comparator

Phase I (acute, double-blind): 5 consecutive daily sessions of sham tDCS (brief ramp-up and ramp-down at the beginning and end of the session, without sustained stimulation) combined with the Sternberg working-memory task (10 minutes at rest, then 10 minutes performing the task). Non-responders then receive Phase II (open-label crossover): 5 consecutive daily sessions of active tDCS. Responders, after Phase I or Phase II, continue to Phase III (maintenance, open-label): active tDCS twice a week for up to 2 months.

Devices: Active tDCS with Sternberg task, Sham tDCS with Sternberg task

Sites

2 sites in 1 country